Physician profile
Robert Roberts
NPI 1518406982
$8,708.94
in general payments reported to CMS, 2019-2025
22 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,906 · 2020: $1,883 · 2021: $612 · 2022: $1,455 · 2023: $840 · 2024: $899 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.56 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $5,766.56 | 2019-2025 | Vibativ, Caldolor, Sancuso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $541.36 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.73 | 2021-2024 | Jardiance |
| Amgen INC. | $345.74 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $301.02 | 2021-2023 | Farxiga, Andexxa |
| Abbott Laboratories | $214.04 | 2022-2024 | Cardiomems, Amplatzer Talisman |
| Amarin Pharma, INC. | $152.10 | 2022-2023 | |
| Novo Nordisk INC | $148.96 | 2021-2023 | Ozempic |
| Medtronic, INC. | $146.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $134.86 | 2022-2024 | Camzyos |
| Regeneron Pharmaceuticals, INC. | $113.16 | 2025 | Dupixent |
| Philips North America LLC | $94.95 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $81.48 | 2023 | Assure Wcd |
| Zoll Respicardia, INC. | $67.82 | 2023-2024 | Remede System |
| Novartis Pharmaceuticals Corporation | $64.40 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $58.84 | 2023-2024 | Xarelto |
| Irhythm Technologies, INC. | $34.99 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Cvrx, INC. | $24.50 | 2024 | Barostim Neo System |
| Itamar Medical INC | $18.89 | 2023 | Watchpatone |
| Alnylam Pharmaceuticals INC. | $17.36 | 2023 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $15.47 | 2024 | Arcalyst |
| Lemaitre Vascular, INC. | $13.80 | 2023 | Cardiocel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.